<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0"
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main" xml:id="_YGueeqd">Proof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled Trial</title>
				<funder ref="#_pNuyAuu">
					<orgName type="full">National Cancer Institute</orgName>
					<orgName type="abbreviated">NCI</orgName>
					<idno type="DOI" subtype="crossref">https://doi.org/10.13039/100000054</idno>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><roleName>PhD, RN</roleName><forename type="first">Sandra</forename><forename type="middle">L</forename><surname>Spoelstra</surname></persName>
							<email>spoelst5@msu.edu</email>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> College of Nursing , Michigan State University , East Lansing , Michigan.</note>
								<orgName type="department">College of Nursing</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<settlement>East Lansing</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Charles</forename><forename type="middle">W</forename><surname>Given</surname></persName>
							<affiliation key="aff1">
								<note type="raw_affiliation"><label>2</label> Departments of Family Medicine ,</note>
								<orgName type="department" key="dep1">Departments</orgName>
								<orgName type="department" key="dep2">Family Medicine</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Alla</forename><surname>Sikorskii</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Statistics and Probability ,</note>
								<orgName type="department">Statistics and Probability</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD</roleName><forename type="first">Constantinos</forename><forename type="middle">K</forename><surname>Coursaris</surname></persName>
							<affiliation key="aff3">
								<note type="raw_affiliation"><label>4</label> Telecommunication, Information Studies, and Media , Michigan State University , East Lansing , Michigan.</note>
								<orgName type="department">Telecommunication, Information Studies, and Media</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<settlement>East Lansing</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhDc</roleName><forename type="first">Atreyee</forename><surname>Majumder</surname></persName>
							<affiliation key="aff2">
								<note type="raw_affiliation"><label>3</label> Statistics and Probability ,</note>
								<orgName type="department">Statistics and Probability</orgName>
							</affiliation>
						</author>
						<author>
							<persName><roleName>RN</roleName><forename type="first">Tracy</forename><surname>Dekoekkoek</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> College of Nursing , Michigan State University , East Lansing , Michigan.</note>
								<orgName type="department">College of Nursing</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<settlement>East Lansing</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>BA</roleName><forename type="first">Monica</forename><surname>Schueller</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> College of Nursing , Michigan State University , East Lansing , Michigan.</note>
								<orgName type="department">College of Nursing</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<settlement>East Lansing</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><roleName>PhD, RN, FAAN</roleName><forename type="first">Barbara</forename><forename type="middle">A</forename><surname>Given</surname></persName>
							<affiliation key="aff0">
								<note type="raw_affiliation"><label>1</label> College of Nursing , Michigan State University , East Lansing , Michigan.</note>
								<orgName type="department">College of Nursing</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<settlement>East Lansing</settlement>
									<region>Michigan</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<note type="raw_affiliation">Lansing Area Research Day , Sigma Theta Tau , Michigan State University/McLaren Cancer Institute , held in Lansing , Michigan , in March 2013 .</note>
								<orgName type="department">Lansing Area Research Day</orgName>
								<orgName type="institution" key="instit1">Sigma Theta Tau</orgName>
								<orgName type="institution" key="instit2">Michigan State University/McLaren Cancer Institute</orgName>
								<address>
									<addrLine>held in Lansing</addrLine>
									<postCode>2013</postCode>
									<region>Michigan in March</region>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<note type="raw_affiliation">College of Nursing Michigan State University 1355 Bogue Street , Room C342 East Lansing , MI 48824</note>
								<orgName type="department">College of Nursing</orgName>
								<orgName type="institution">Michigan State University</orgName>
								<address>
									<addrLine>1355 Bogue Street Room C342</addrLine>
									<postCode>48824</postCode>
									<settlement>East Lansing</settlement>
									<region>MI</region>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main" xml:id="_BdFH62X">Proof of Concept of a Mobile Health Short Message Service Text Message Intervention That Promotes Adherence to Oral Anticancer Agent Medications: A Randomized Controlled Trial</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">1CDF009A2B85541D2CB0E695636EC699</idno>
					<idno type="DOI">10.1089/tmj.2015.0126</idno>
					<note type="submission">Received: July 9, 2015 Revised: September 9, 2015 Accepted: September 9, 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.2" ident="GROBID" when="2025-08-31T04:56+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<label type="revision">a91ee48</label>
					<label type="parameters">startPage=-1, endPage=-1, consolidateCitations=2, consolidateHeader=2, consolidateFunders=1, includeRawAffiliations=true, includeRawCitations=true, includeRawCopyrights=true, generateTeiIds=true, generateTeiCoordinates=[all], sentenceSegmentation=true, flavor=null</label>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term xml:id="_vQbYvwk">behavioral health</term>
					<term xml:id="_9SMJjFE">mobile health</term>
					<term xml:id="_xwxBpqw">technology</term>
					<term xml:id="_GJCxgga">teleoncology</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0" xml:id="_Zxj7AgH"><p xml:id="_NbmWdQD"><s xml:id="_QRzGM8M">Introduction: This multisite, randomized controlled trial assigned 75 adult cancer patients prescribed an oral anticancer agent to either an experimental group that received daily text messages for adherence for 21 days plus usual care or a control group that received usual care.</s><s xml:id="_cvHUbdp">Materials and Methods: Measures were administered at baseline, weekly (Weeks 1-8), and at exit (Week 9).</s><s xml:id="_wCHWM56">A satisfaction survey was conducted following the intervention.</s><s xml:id="_XpbUJ7H">Acceptability, feasibility, and satisfaction were examined.</s><s xml:id="_wuV3JX7">Primary outcomes were adherence and symptoms.</s><s xml:id="_hRbYK2K">Secondary outcomes were depressive symptoms, self-efficacy, cognition, physical function, and social support.</s><s xml:id="_srbxAE2">Mixed or general linear models were used for the analyses comparing trial groups.</s><s xml:id="_P6KWnN6">Effect sizes (ES) were estimated to gauge clinical significance.</s><s xml:id="_88ZKhPd">Results: Regarding acceptability, 57.2% (83 of 145) of eligible patients consented, 88% (n = 37 of 42) receiving text messages read them most or all of the time, and 90% (n = 38) were satisfied.</s><s xml:id="_az4V9MM">The differences between experimental and control groups' ES were 0.29 for adherence, 0.21 for symptom severity, and 0.21 for symptom interference, and differences were not statistically significant.</s><s xml:id="_yyfeckq">Furthermore, perceived social support was higher (p = 0.04; ES = 0.54) in the experimental group.</s><s xml:id="_rkzfpFR">Conclusions: Proof of concept and preliminary efficacy of a mobile health intervention using text messages to promote adherence for patients prescribed oral anticancer agents were demonstrated.</s><s xml:id="_G88WuF4">Patients accepted and had high satisfaction with the intervention, and adherence improved after the intervention.</s><s xml:id="_CUG76Vz">Text messages show promise.</s><s xml:id="_6HGUXh8">Additional research is needed prior to use in practice.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<facsimile>
		<surface n="1" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="2" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="3" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="4" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="5" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="6" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="7" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="8" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="9" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
		<surface n="10" ulx="0.0" uly="0.0" lrx="612.0" lry="792.0"/>
	</facsimile>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_rqEFnc2">Introduction</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_2f4g57x">W</head><p xml:id="_Q4hkK3r"><s xml:id="_GcpMCwM">ith more than 50 oral anticancer agents (OAs) on the market, it is projected that within the next decade, 25% of cancer treatment will be in pill form. <ref type="bibr" target="#b0">1</ref> Recent reviews on OAs indicate adherence rates are often less than 80%. <ref type="bibr" target="#b1">2,</ref><ref type="bibr" target="#b2">3</ref></s><s xml:id="_BNUKm67">OAs often come with side effects, which in turn may lead to adverse events and nonadherence. <ref type="bibr" target="#b2">3</ref></s><s xml:id="_hmVMqcN">OA treatment requires patients to self-manage side effects from treatment and adherence in the home setting. <ref type="bibr" target="#b3">4</ref></s><s xml:id="_dDZGJkT">ost cancer patients are older and also have comorbid conditions and take multiple medications, which likely make symptoms more severe, as well as adherence more difficult. <ref type="bibr" target="#b4">5</ref></s><s xml:id="_mjVMg7S">ther known factors that may influence adherence include medication frequency and complexity, adverse effects of the medication, forgetfulness, beliefs about importance of taking the medication, or inability to pay. <ref type="bibr" target="#b5">6</ref></s><s xml:id="_drfSR7r">The available evidence suggests self-management of OAs is a significant clinical problem that may impact treatment success or failure. <ref type="bibr" target="#b6">7,</ref><ref type="bibr" target="#b7">8</ref></s><s xml:id="_yt7e4WG">ell phones have been widely adopted and are rapidly evolving as a cost-effective mode of delivering tailored behavioral interventions. <ref type="bibr" target="#b8">9,</ref><ref type="bibr" target="#b9">10</ref></s><s xml:id="_NKsj6bg">There are more than 285 million cell phone subscribers in the United States, <ref type="bibr" target="#b10">11</ref> and it is estimated 81% of users send and receive text messages (TMs). <ref type="bibr" target="#b11">12</ref></s><s xml:id="_DE2Cn6U">vidence is beginning to show that TMs built on Social Cognitive Theory <ref type="bibr" target="#b12">13</ref> increase self-efficacy and improve health outcomes. <ref type="bibr" target="#b13">14</ref></s><s xml:id="_FjxXMtC">TMs have also improved medication adherence in multiple diseases, <ref type="bibr" target="#b5">6</ref> with one trial finding more correct medication doses taken on time. <ref type="bibr" target="#b14">15</ref></s><s xml:id="_WWyXWzs">atients who are prescribed OAs are often vulnerable, as most are older, have comorbidities, or are receiving the OA as a second or third line of cancer treatment over an extended period of time.</s><s xml:id="_kC6WnSY">Thus, OA adherence is challenging.</s><s xml:id="_qwmuQW3">The purpose of this study was to examine proof of concept of a TM intervention and to conduct a preliminary evaluation of the efficacy of TMs with respect to adherence and symptom severity and interference in adult cancer patients prescribed OAs.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_9MWA3z6">Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ge6uuUg">STUDY DESIGN</head><p xml:id="_3KaRxkm"><s xml:id="_pGmuaQP">This study used a multisite, longitudinal (10-week), randomized controlled trial design with two groups: the experimental group with 21 days of short message service TMs for adherence plus usual care and a control group with usual care (2:1 allocation ratio).</s><s xml:id="_ywEuraC">Assessments occurred at baseline before random assignment, weekly, and at exit.</s><s xml:id="_q5bVPg3">The satisfaction survey occurred immediately after TMs ended.</s><s xml:id="_8u35V9g">The protocol was approved by the institutional review boards at each site and was published previously. <ref type="bibr" target="#b15">16</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ZmrBF4b">INCLUSION AND EXCLUSION CRITERIA</head><p xml:id="_bpNP47Z"><s xml:id="_tZDvkAr">Inclusion criteria were being 21 years of age or older, having been newly prescribed an OA within the past 30 days, owning a personal cell phone, and being willing and able to receive and send TMs.</s><s xml:id="_UaHkR8Q">Patients with cognitive impairment that limited their ability to understand and answer questions and those who did not speak and read English were excluded.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4tnkKW3">RECRUITMENT</head><p xml:id="_kyNUGhW"><s xml:id="_CUF3EVZ">Recruitment occurred between October 2013 and October 2014 at four community cancer centers in the Midwest, a national comprehensive cancer center in the East, and a large specialty pharmacy that serves the United States.</s><s xml:id="_rd6Db5G">At the cancer centers, medical records were screened to identify those eligible by recruiters, who were nurses or physician assistants.</s><s xml:id="_cMqpNqJ">Recruiters approached patients face to face, explained the study, and obtained informed consent from those willing to participate.</s><s xml:id="_ADSHJzf">At the specialty pharmacy, dispensing records were screened to identify those eligible by recruiters, who were pharmacists or pharmacy technicians.</s><s xml:id="_6MmRqh4">Recruiters sent a letter explaining the study, with a consent form and return envelope to mail the signed consent form back to the specialty pharmacy if the patient was willing to participate.</s><s xml:id="_PDqDHfg">Recruiters also called on the phone, explained the study, and obtained informed consent via an electronic e-mail signature.</s><s xml:id="_3QUzqJX">All recruiters recorded the number of patients who were contacted and the subsequent accrual rates.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_pBJ8WVa">PROCEDURES</head><p xml:id="_CtaaK3j"><s xml:id="_PFyVDZW">After consents to participate were obtained, baseline interviews (Week 0) were conducted by phone.</s><s xml:id="_ZMDXdZT">An automated voice response system was used to complete weekly assessments (Weeks 1-8) of OA adherence and 19 commonly experienced symptoms.</s><s xml:id="_J85vDYH">Satisfaction surveys were conducted at the completion of the TMs (Week 4) by phone.</s><s xml:id="_w2ySnJM">Exit interviews were conducted by phone at the end of the study (Week 9).</s><s xml:id="_a6v8KSw">Medical records were audited at the end of the study to gather data on the prescribed dosages of OAs, dose changes, and stoppages.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_xq6zYwM">RANDOM ASSIGNMENT AND BLINDING</head><p xml:id="_atxVxCq"><s xml:id="_5jXRVJm">After baseline data were collected, participants were randomly assigned using a 2:1 ratio of experimental to control condition using a minimization algorithm, designed by the biostatistician in SAS version 9.4 software (SAS Institute, Cary, NC).</s><s xml:id="_jQxfn45">The minimization balanced the groups on age (&lt;50 or ‡50 years) and recruitment site.</s><s xml:id="_uewfh8h">The intervention began at the time the patient started the OA prescription or within 7 days of random assignment if patients had already started the OA.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_79Uwugk">INTERVENTION</head><p xml:id="_sJP6TBB"><s xml:id="_t58cZwp">Theory-based TMs were developed according to Social Cognitive Theory using 160 characters or less (Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s xml:id="_bwkQscf">This included a welcome and test TM (e.g., ''Welcome to the study.</s><s xml:id="_3GXaTJg">For 21 days, you will receive text message reminders to take your cancer pills.</s><s xml:id="_X2SXCNS">Reply 'OK' after reading this message''), six medication adherence TMs used on a rotating basis (e.g., ''A reminder to take your [drug name] now.</s><s xml:id="_C6wcbeS">Doing so is an important step in managing your cancer.</s><s xml:id="_UbhSTCC">Reply 'Taken' when you've taken it''), and an end-of-study TM (e.g., ''Our study is over.</s><s xml:id="_qeBP5sp">Remember: it is both easy and important to take your cancer pills as prescribed.</s><s xml:id="_AWRw2XA">If you have questions call your clinician.</s><s xml:id="_6CeV43e">Thank you'').</s><s xml:id="_48M26Rx">An automated platform delivered the TMs and stored associated data.</s><s xml:id="_Zpqc5Er">Patient name, cell phone number, OA medication name, and delivery time for TMs (regimen schedule) were entered in the platform to send the TMs after randomization.</s><s xml:id="_9B4xQUQ">The experimental group patients were sent the test TM to confirm the cell phone number and assure they were able to respond by TM.</s><s xml:id="_7QYyC7a">Adherence TMs were delivered at the time of day the OA was to be taken for 21 days.</s></p><p xml:id="_Rqk4JDy"><s xml:id="_XcQXB3B">Patients were asked to respond by TM if the OAs were ''taken.''</s><s xml:id="_BrmedTv">Upon completion of the intervention, a final, end-of-study TM was sent.</s><s xml:id="_tMUpVUP">To assure TMs were not sent when patients were not prescribed to take the OA, regimen schedules were confirmed with the recruiter and patient.</s><s xml:id="_cZvCdgK">Patients were also trained to inform the study office of OA changes, such as reduction, interruption, or stoppage of the medication.</s><s xml:id="_Bhexhkv">Patients were also asked to password-protect their cell phone to assure privacy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_X9zNn5t">USUAL CARE</head><p xml:id="_tKeadST"><s xml:id="_arxsxMs">Usual care included instructions and information provided by oncologists, nurses, or pharmacists on the OA regimen, side effects, managing symptoms, medication adherence and safety, and how to contact a clinician if problems arose.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yv3AqVW">MEASURES</head><p xml:id="_97nB837"><s xml:id="_QQZqzcH">Background.</s><s xml:id="_xW3TDwc">Demographics (age, sex, race and ethnicity, marital status, education level, and employment) and comorbid conditions were assessed.</s></p><p xml:id="_HFssCk5"><s xml:id="_wPevZdX">Disease parameters and treatment.</s><s xml:id="_WCkfn75">Record reviews were conducted to determine cancer type and stage of disease, as well as OA regimen prescription at the time of study enrollment.</s></p><p xml:id="_wJdWS5v"><s xml:id="_ZFc5W9b">Proof of concept.</s><s xml:id="_TmcbZsF">Acceptability of TMs was measured by the number of patients who accepted enrollment out of the number offered to participate, as well as by the percentage of patients who completed the study.</s><s xml:id="_RsrESw7">Feasibility was measured by the number of TMs delivered and returned.</s><s xml:id="_6hWCHQw">Satisfaction with TMs was measured using a tool developed in previous studies. <ref type="bibr" target="#b16">17,</ref><ref type="bibr" target="#b17">18</ref></s><s xml:id="_q53ShyS">atisfaction was deemed high for scores exceeding 80%.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_DZ8392t">PRIMARY OUTCOME MEASURES</head><p xml:id="_BjSSbvS"><s xml:id="_Acqhyk6">Adherence was measured by report by patients of whether they took the OA pills as prescribed over the past 7 days and by pill counts during the exit interview.</s><s xml:id="_NDrsgJQ">Feasibility of calculating the relative dose intensity, an additional measure of adherence that is determined by the ratio of delivered dose of OA given over a period of time in relation to what was prescribed, was evaluated. <ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref></s><s xml:id="_7fJQYrv">]<ref type="bibr" target="#b20">[21]</ref> Severity and interference with daily life of 19 symptoms were assessed using the Symptom Inventory <ref type="bibr" target="#b21">22,</ref><ref type="bibr" target="#b22">23</ref> at baseline, weekly, and at exit.</s><s xml:id="_E8Dh2YR">Each symptom was rated as to its presence in the past week (yes/no), severity on the scale from 1 (very little) to 9 (worst possible), and interference with daily life on the scale from 0 (no interference) to 9 (interfered completely).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_zmJbx34">SECONDARY OUTCOME MEASURES</head><p xml:id="_Ta5uzQU"><s xml:id="_t5x6bUC">Measures of secondary outcomes were obtained at baseline and exit.</s><s xml:id="_4DUCnK9">Cognition was assessed using the Attentional Function Inventory for cancer patients, which examines three constructs in subscales: effective action, attentional lapses, and interpersonal effectiveness. <ref type="bibr" target="#b23">24</ref></s><s xml:id="_3jj5tbj">Patient Reported Outcomes Measurement Information System (PROMIS) tools were used to assess depression (8a) and physical function (6a). <ref type="bibr" target="#b24">25</ref></s><s xml:id="_azZjmKm">Self-efficacy was assessed using the Medication Adherence Self-Efficacy Scale, <ref type="bibr" target="#b25">26</ref> the Self Efficacy Adherence Medications, <ref type="bibr" target="#b26">27</ref> and the Brief Medication Questionnaire (Specific). <ref type="bibr" target="#b27">28</ref></s><s xml:id="_eXRfuRR">Social support was assessed using the Medication Specific Social Support tool. <ref type="bibr" target="#b28">29</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_c5bQnC4">DATA ANALYSIS</head><p xml:id="_cJySett"><s xml:id="_rftBtPk">Descriptive statistics, including frequency distributions, measures of central tendency, skewness, and variability, were evaluated for variables of interest.</s><s xml:id="_xvaaQ8e">Baseline equivalence of groups created by the randomization was verified using chisquared, Fisher's exact, or t tests.</s><s xml:id="_XSEKCz2">To determine acceptability, feasibility, and satisfaction of TMs among patients on OAs, the proportions of patients who agreed to participate, attrition reasons, and characteristics of patients who dropped out from the study were summarized.</s><s xml:id="_2d8heRV">The proportions of TMs received and returned were described, as was satisfaction.</s><s xml:id="_kSSK994">To determine preliminary efficacy of TMs on adherence, as well as secondary outcomes of symptom severity, depressive symptoms, physical function, cognitive function, self-efficacy, and social support, general linear or mixed modeling was used.</s><s xml:id="_SAa89Ft">The covariates included study group and outcome value at baseline.</s><s xml:id="_AuDZG3n">Value at baseline was not applicable for self-reported adherence measures; thus for those outcomes general linear models included only one explanatory variable, the study group.</s><s xml:id="_DVjb7pR">Effect sizes (ES) were computed as Cohen's d-the difference between group adjusted means expressed in the adjusted standard deviation units (square root of the mean square error)-to gauge clinical significance and inform planning of a larger study. <ref type="bibr" target="#b29">30,</ref><ref type="bibr" target="#b30">31</ref></s><s xml:id="_kF22Baa">SAS version 9.4 software (SAS Institute, Cary, NC) was used for the data analysis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_gYaNM5g">Results</head><p xml:id="_YhJabRn"><s xml:id="_DbGwuz5">The flow of participants is depicted in Figure <ref type="figure" target="#fig_1">2</ref>. In total, 1,356 TMs were sent to patients in this study.</s><s xml:id="_Vr4DdaG">This included 1,189 TMs for adherence: 741 TMs were sent at the time the OAs were to be taken, and 448 repeat TMs were sent when the patient did not reply with the correct response text.</s><s xml:id="_NDN2npV">In addition, 49 test TMs and 49 end-of-study TMs were sent.</s><s xml:id="_yMC6Njb">Patients replied via 1,036 TMs, 87.1% of the time (1,036 of 1,189).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_q7t9NFs">PARTICIPANTS</head><p xml:id="_V957VFb"><s xml:id="_ycpvuP9">Of the 198 patients screened, 78 consented, and 75 of them completed baseline interviews.</s><s xml:id="_4NqJc9q">Randomization yielded 49 in the experimental group and 26 in the control group.</s><s xml:id="_zgwPvmy">Table <ref type="table" target="#tab_0">1</ref> details the sample characteristics.</s><s xml:id="_cgZPpGq">No differences in sociodemographic, clinical, or psychological characteristics were found among groups at baseline.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_J5zcW9M">ATTRITION</head><p xml:id="_RfkAyyt"><s xml:id="_9fqNGXw">Following baseline interview and randomization, 4 patients were lost to follow-up, 2 decided they did not want TMs but continued with automated voice response assessments, 1 no longer wanted to participate, and 1 was too sick to continue in the experimental group.</s><s xml:id="_4jbSaDG">In the control group, 2 patients were lost to follow-up.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_Sa7XXP3">PROOF OF CONCEPT</head><p xml:id="_5K9f3yH"><s xml:id="_w6RA7hD">Regarding acceptability, 75.7% (78 of 103) of eligible patients consented.</s><s xml:id="_jx4JQYb">No difference in age was found according to eligi-bility and consent, but a significant difference was observed in enrollment by sex between consented versus eligible but not enrolled ( p = 0.02) (Table <ref type="table" target="#tab_0">1</ref>).</s><s xml:id="_9eZrZ5d">Of those who were ineligible, 41.1% (39 of 95) did not have a cell phone, 33.7% (32 of 95) did not use TMs, and 23.2% (22 of 95) were no longer prescribed an OA.</s><s xml:id="_tTGbM4J">Regarding feasibility, of those who were eligible but chose not to enroll, 92% (23 of 25) were not interested.</s></p><p xml:id="_m8PQysM"><s xml:id="_CkNDjfM">Regarding satisfaction (Table <ref type="table" target="#tab_2">2</ref>), 39 completed the survey.</s><s xml:id="_4c4ga8w">It is notable that, in this sample of very ill cancer patients, many of whom were on their second or third line of treatment, 85.7% (42 of 49 participants) completed the entire TM intervention, further confirming acceptability of this intervention.</s><s xml:id="_fhMqgh6">Of those who completed the survey, 78.9% (n = 30) read the TMs all the time, and 18.4% (n = 7) read the TM most of the time.</s><s xml:id="_GKFXWpS">The majority of patients (92.2%, n = 35) reported high satisfaction with receiving the TMs.</s><s xml:id="_wgQH7KG">Overall, 97.4% (n = 38) recommended TMs as a way to help patients remember to take OAs, and 100% (n = 39) would recommend TMs to their oncologist as a way to monitor adherence.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_RfQQg3B">PRIMARY OUTCOMES: ADHERENCE AND SYMPTOMS</head><p xml:id="_TPzp8w2"><s xml:id="_ECgDxXn">Table <ref type="table" target="#tab_3">3</ref> provides a weekly summary of self-reported OA adherence in the experimental and control groups for Weeks 1-8 and the exit interview.</s><s xml:id="_ntcY5nM">The control group started with a higher percentage of OA adherence in Week 1 (73.1%,</s><s xml:id="_Aasr7e8">n = 19) compared with the experimental group (66%, n = 31), and as shown in Table <ref type="table" target="#tab_3">3</ref>, Weeks 2-6 and 8 had higher percentages of OA adherence in the control group.</s><s xml:id="_chABTwU">The control group had declining adherence over time, whereas the experimental group had increasing OA adherence over time.</s><s xml:id="_Pd5wtFG">Week 7 and exit had higher adherence in the experimental group (70.2% versus 61.5% and 86.7% versus 79.2%, respectively).</s><s xml:id="_uu5xEJz">The mean number of weeks of adherence to OAs in the experimental group was 6.5 (standard error = 0.4) compared with 7.2 (standard error = 0.5) in the control group ( p = 0.26), with an ES of -0.29 (Table <ref type="table" target="#tab_4">4</ref>).</s><s xml:id="_2fXM8mw">This difference was not statistically significant with the available sample size.</s><s xml:id="_MHzQGBQ">We were unable to calculate relative dose intensity as an objective measure of adherence from medical record and prescription data audits (n = 75), as we did not obtain good agreement of patient self-report and medical record documentation of dose changes, number of refills prescribed, and number of refills reported by patients.</s><s xml:id="_FHPDn6w">For example, of 59 patients with no dose changes documented in the medical records, 5 (8%) said the dose was changed; of 65 patients who did not report any dose changes, 11 (17%) had dose changes documented in the medical records.</s></p><p xml:id="_qaSnE6D"><s xml:id="_GYhAGU6">The number of symptoms and summed symptom severity and interference did not significantly differ by study arm (Table <ref type="table" target="#tab_5">5</ref>).</s><s xml:id="_gxs7Skx">Table <ref type="table" target="#tab_4">4</ref> reports on group differences postintervention.</s><s xml:id="_8s6bJbC">Although not significant, the experimental group had fewer total number of symptoms (ES = 0.09), lower summed symptom severity (ES = 0.21), and lower summed interference (ES = 0.22), all having small ES.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_huCA4PB">SECONDARY OUTCOMES</head><p xml:id="_AdFF4zv"><s xml:id="_8NRAtY6">There were no group differences on physical function (ES = -0.06)</s><s xml:id="_S6E9t63">or on the three subscales on cognitive function (effective action, attentional lapses, and interpersonal effectiveness), and the ES for group differences were small.</s><s xml:id="_PyU22Rq">Similarly, the three self-efficacy measures demonstrated small ES differences in the experimental group compared with the control: the Brief Medication Questionnaire-1 (ES = 0.04), the Brief Medication Questionnaire-2 (ES = 0.08), the Medication Adherence Self-Efficacy Scale (ES = -0.06),</s><s xml:id="_qf9wUfR">and the Self Efficacy Adherence Medications (ES = -0.44)</s><s xml:id="_pS9WJeM">(the last was only done at exit).</s><s xml:id="_X4mkdn7">The experimental group differed significantly from the control group on Medication Social Support ( p = 0.4, ES = 0.54).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_4u7eHn7">Discussion</head><p xml:id="_YfUZyME"><s xml:id="_juD9sw6">This study demonstrated proof of concept of TMs to promote self-management of adherence for patients prescribed OAs.</s><s xml:id="_a3pJtzz">Among the eligible patients, age was not related to willingness to send/receive TMs, whereas females were more likely to send/receive TMs.</s><s xml:id="_D7VPKbM">Patients were multimorbid, with many symptoms that interfered with activities of daily life.</s><s xml:id="_uvWGF9z">In this sample of cancer patients, TMs demonstrated feasibility as an intervention, with most patients reading the TM.</s><s xml:id="_aK3Qx6p">Satisfaction was high for medication adherence and monitoring, demonstrating that patients thought TMs were helpful.</s></p><p xml:id="_G2CQH9Q"><s xml:id="_7v48rfX">Did not help 2 (</s></p><p xml:id="_Gzn7rqj"><s xml:id="_FnVdbAd">How satisfied were you with text reminders to take your medications?</s><s xml:id="_tTErPDd">a Not at all 1 (2.6) 0 (0.0) 0 (0.0) 1 (4.2) 0 (0.0) 1 (4.</s><s xml:id="_EWh9sBU">The self-reported medication adherence measure showed improving adherence rates in the experimental group at later weeks, suggesting that a patient may start with good adherence but may need the support of TMs later.</s><s xml:id="_AbnbmZt">Self-report is the most widely used method of assessment medication adherence; however, there are several shortcomings.</s><s xml:id="_N8unVNs">Self-reporting has the problem of overestimating adherence; inaccuracies can also be caused by recall bias, social desirability bias, and errors in self-observation. <ref type="bibr" target="#b31">32,</ref><ref type="bibr" target="#b32">33</ref></s><s xml:id="_fJHrzUR">rthermore, the time frame of adherence recollection can affect the accuracy of the recall during self-report. <ref type="bibr" target="#b33">34</ref></s><s xml:id="_wSMVxNE">TM reminders may sensitize patients to missed doses, and they may be more likely to report missed doses compared with patients not receiving reminders.</s></p><p xml:id="_zKTJKVN"><s xml:id="_ppDQQRs">Wording of questions, the way the medication adherence question is asked, and the skills of the interviewer can either facilitate or be detrimental to obtaining measures of medication adherence. <ref type="bibr" target="#b31">32</ref></s><s xml:id="_pyXkxsn">When assessing relative dose intensity, we experienced difficulty obtaining objective data from medical and pharmacy dispensing records to determine if the oncologist had increased, decreased, or stopped OA dosages.</s><s xml:id="_v9SW3cy">Thus, measuring medication adherence remains a challenge for both clinicians and scientists.</s><s xml:id="_2Ac7F7M">Finally, although we did not find differences in measures of self-efficacy in this small sample, the scripted TMs based on Social Cognitive Theory were thought to be encouraging and motivating to patients, as shown in patient remarks in satisfaction surveys, and began to show promise at engaging behavior change in the form of improved adherence over the course of the study toward the later weeks.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_V4Mndwu">LIMITATIONS</head><p xml:id="_t9s8Ga5"><s xml:id="_CDr6rxh">The majority of patients were recruited shortly after they were informed of a new cancer diagnosis or after other treatment failure.</s><s xml:id="_Nq39DHE">Consequently, in either situation, patients may have experienced high levels of stress, which may have led to a difficulty with completing data collection during our weekly assessments (78.9%, or 442 of 560, automated voice response assessments were completed).</s><s xml:id="_cdG3a5Z">This study was not powered to detect differences between groups on the secondary outcome measures but to compute ES for a larger study.</s><s xml:id="_TnPa3AE">Challenges in the measurement of medication adherence described above remain a limitation in this study, as well as in many studies of medication adherence.</s><s xml:id="_WjqGp7z">Measuring adherence by self-report is limited by the ability to recall if the medication was taken.</s><s xml:id="_Cdc9uYn">Pharmacy dispensing records do not capture all instances of OA dose reductions or temporary stoppages.</s><s xml:id="_UEBYpdU">Medical record audits may be incomplete and may not agree with patient reports.</s><s xml:id="_tMFm4NM">Thus, objective adherence measurement for the sample, as in many medication adherence studies, was challenging.</s></p><p xml:id="_MtXSmx6"><s xml:id="_BwmtX2r">TM interventions are feasible in cancer patients prescribed OAs for medication adherence and may be effective in helping patients engage in behavior change and improve selfmanagement.</s><s xml:id="_Y7xwq23">Use of cell phones is increasing dramatically, and TMs may be an easy mode of delivering healthcare to large numbers of patients.</s><s xml:id="_RVpUazb">Future work is needed to examine the efficacy of TMs at improving medication adherence in larger clinical trials across multiple disease conditions and age groups, in particular with technology-based interventions of different types such as TMs, automated voice response, and applications.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_ADXQVra">TEXT MESSAGES TO IMPROVE CANCER MEDICATION ADHERENCE</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head xml:id="_yFWvkdK">Disclosure Statement</head><p xml:id="_wwPWyWa"><s xml:id="_hdEj53e">No competing financial interests exist.</s><s xml:id="_FXj9Y2W">S.L.S., C.W.G., A.S., C.K.C., and B.A.G. are responsible for study conception and design.</s><s xml:id="_csfRedF">S.L.S., A.S., T.D., and M.S. are responsible for collection and assembly of data.</s><s xml:id="_nWfQY6B">All authors are responsible for data analysis and interpretation, manuscript writing, and final approval of the manuscript.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p xml:id="_GgfVJtB"><s xml:id="_vQqVRBd">Fig. 1.</s><s xml:id="_FxxerS8">Text message designed using Social Cognitive Theory.</s><s xml:id="_qKe8SCD">xxx* represents the brand name of the oral anticancer agent to be taken by the patient.</s></p></div></figDesc><graphic coords="3,67.41,99.44,463.14,202.00" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Fig. 2 .</head><label>2</label><figDesc><div><p xml:id="_kJaCPnX"><s xml:id="_p7V7e9m">Fig. 2. Modified Consolidated Standards of Reporting Trials flowchart, showing intent-to-treat and randomization for the experimental and control groups.</s><s xml:id="_wJTH5FA">AVR, automated voice response; OA, oral anticancer agent; TM, text message.</s></p></div></figDesc><graphic coords="5,43.65,99.44,514.48,575.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>6 )</head><label>6</label><figDesc><div><p xml:id="_aEGgwbY"><s xml:id="_aUFQA4v">Did you read the text messages about your cancer pills? a All of the time 30 text messages as a reminder to take your cancer pills?</s><s xml:id="_j552Q94">text messages as a way for clinicians to monitor if cancer pills were taken?</s><s xml:id="_aWGRCyY">are number (%). a Some data are missing.</s><s xml:id="_2rPRYh4">TEXT MESSAGES TO IMPROVE CANCER MEDICATION ADHERENCE ª M A R Y A N N L I E B E R T , I N C .</s><s xml:id="_7rvkSU2">VOL. 22 NO.</s><s xml:id="_BGqYVGG">6 JUNE 2016 TELEMEDICINE and e-HEALTH 503</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_7qqB689"><s xml:id="_maVKM7e">Baseline Characteristics of Study Participants, According to Study Group</s></p></div></figDesc><table><row><cell></cell><cell>TM</cell><cell>CONTROL</cell><cell></cell></row><row><cell>CHARACTERISTIC</cell><cell>(N = 49)</cell><cell>(N = 26)</cell><cell>P</cell></row><row><cell>Age (years) [mean (SD)]</cell><cell>60.1 (10.1)</cell><cell>59.9 (11.2)</cell><cell>0.90</cell></row><row><cell>Sex [n (%)]</cell><cell></cell><cell></cell><cell>0.70</cell></row><row><cell>Male</cell><cell>23 (46.9)</cell><cell>11 (42.3)</cell><cell></cell></row><row><cell>Female</cell><cell>26 (53.1)</cell><cell>15 (57.7)</cell><cell></cell></row><row><cell>Race [n (%)] a</cell><cell></cell><cell></cell><cell>0.51</cell></row><row><cell>White</cell><cell>44 (89.8)</cell><cell>22 (84.6)</cell><cell></cell></row><row><cell>Other</cell><cell>5 (10.2)</cell><cell>4 (15.4)</cell><cell></cell></row><row><cell>Ethnicity [n (%)]</cell><cell></cell><cell></cell><cell>-</cell></row><row><cell>Not Hispanic or Latino</cell><cell>49 (100.0)</cell><cell>26 (100.0)</cell><cell></cell></row><row><cell>Education [n (%)] a</cell><cell></cell><cell></cell><cell>0.67</cell></row><row><cell>Some college/bachelor's degree</cell><cell>27 (55.1)</cell><cell>13 (50.0)</cell><cell></cell></row><row><cell>Other</cell><cell>22 (44.9)</cell><cell>13 (50.0)</cell><cell></cell></row><row><cell>Employment [n (%)]</cell><cell></cell><cell></cell><cell>0.74</cell></row><row><cell>Employed</cell><cell>17 (34.7)</cell><cell>10 (38.5)</cell><cell>0.18</cell></row><row><cell>Not employed</cell><cell>32 (65.3)</cell><cell>16 (61.5)</cell><cell></cell></row><row><cell>Comorbidity [n (%)] a</cell><cell></cell><cell></cell><cell>0.19</cell></row><row><cell>Arthritis</cell><cell>17 (21.5)</cell><cell>11 (33.3)</cell><cell></cell></row><row><cell>Other</cell><cell>62 (78.5)</cell><cell>22 (66.7)</cell><cell></cell></row><row><cell>Comorbidities (total number) [mean (SD)]</cell><cell>1.6 (1.5)</cell><cell>1.3 (1.2)</cell><cell>0.33</cell></row><row><cell>Site of cancer [n (%)] a</cell><cell></cell><cell></cell><cell>0.82</cell></row><row><cell>Breast</cell><cell>12 (24.5)</cell><cell>7 (26.9)</cell><cell>-</cell></row><row><cell>Other</cell><cell>37 (75.5)</cell><cell>19 (73.1)</cell><cell></cell></row><row><cell>Cancer stage [n (%)]</cell><cell></cell><cell></cell><cell>0.82</cell></row><row><cell>IV</cell><cell>25 (51.0)</cell><cell>14 (53.9)</cell><cell></cell></row><row><cell>Other</cell><cell>24 (49.0)</cell><cell>12 (46.1)</cell><cell></cell></row><row><cell>Complexity of dosing of oral agent [n (%)]</cell><cell></cell><cell></cell><cell>0.39</cell></row><row><cell>Simple</cell><cell>17 (35.4)</cell><cell>7 (26.9)</cell><cell></cell></row><row><cell>Complex</cell><cell>31 (64.6)</cell><cell>19 (73.1)</cell><cell></cell></row><row><cell>Symptoms [mean (SD)]</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total number</cell><cell>4.9 (2.9)</cell><cell>5.7 (3.5)</cell><cell>0.32</cell></row><row><cell>Summed severity</cell><cell>24.5 (19.6)</cell><cell>31.6 (19.7)</cell><cell>0.16</cell></row><row><cell>Summed interference</cell><cell>18.8 (17.9)</cell><cell>31.6 (20.9)</cell><cell>0.63</cell></row><row><cell>PROMIS [mean (SD)]</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Depression</cell><cell>45.5 (7.2)</cell><cell>47.4 (8.4)</cell><cell>0.31</cell></row><row><cell>Physical function</cell><cell>45.0 (7.5)</cell><cell>44.2(8.2)</cell><cell>0.65</cell></row><row><cell></cell><cell></cell><cell cols="2">continued /</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 1 .</head><label>1</label><figDesc><div><p xml:id="_ZtY9gQa"><s xml:id="_buPnpRc">continued</s></p></div></figDesc><table><row><cell></cell><cell>TM</cell><cell>CONTROL</cell><cell></cell></row><row><cell>CHARACTERISTIC</cell><cell>(N = 49)</cell><cell>(N = 26)</cell><cell>P</cell></row><row><cell>Cognitive function [mean (SD)]</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Effective action subscale</cell><cell>48.6 (14.2)</cell><cell>46.1 (16.0)</cell><cell>0.49</cell></row><row><cell>Attentional lapses subscale</cell><cell>23.7 (5.9)</cell><cell>21.8 (7.4)</cell><cell>0.23</cell></row><row><cell>Interpersonal effectiveness subscale</cell><cell>21.9 (5.8)</cell><cell>20.1 (6.7)</cell><cell>0.22</cell></row><row><cell>Self-efficacy [mean (SD)]</cell><cell></cell><cell></cell><cell></cell></row><row><cell>BMQ1</cell><cell>10.2 (3.8)</cell><cell>10.5 (4.5)</cell><cell>0.78</cell></row><row><cell>BMQ2</cell><cell>19.7 (3.7)</cell><cell>15.6 (4.4)</cell><cell>0.26</cell></row><row><cell>MASES-R</cell><cell>30.2 (4.7)</cell><cell>29.4 (1.2)</cell><cell>0.49</cell></row><row><cell>Social support [mean (SD)]</cell><cell>4.6 (3.4)</cell><cell>4.8 (3.2)</cell><cell>0.78</cell></row></table><note xml:id="_xsgcM5s"><p><s xml:id="_9dqPV9N">a Due to some of the counts being small, p values reflect group comparisons of proportions in the most prevalent category.</s><s xml:id="_cJ6dSvg">BMQ, Brief Medication Questionnaire; MASES-R, Medication Adherence Self-Efficacy Scale; PROMIS, Patient Reported Outcomes Measurement Information System; TM, text message.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 2 .</head><label>2</label><figDesc><div><p xml:id="_Q6gxa28"><s xml:id="_K7VjcE7">Summary of Responses to the Satisfaction Survey by Age Groups and Gender</s></p></div></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>AGE (YEARS)</cell><cell></cell><cell>SEX</cell><cell></cell></row><row><cell>QUESTION</cell><cell>ALL PATIENTS</cell><cell>£50</cell><cell>51-64</cell><cell>65+</cell><cell>MALE</cell><cell>FEMALE</cell></row><row><cell cols="2">How satisfied are you overall with your participation in the study? a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Not at all</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell></row><row><cell>Somewhat</cell><cell>1 (2.7)</cell><cell>0 (0.0)</cell><cell>1 (10.0)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>1 (4.8)</cell></row><row><cell>Very much</cell><cell>13 (35.1)</cell><cell>1 (25.0)</cell><cell>2 (20.0)</cell><cell>10 (43.4)</cell><cell>7 (43.4)</cell><cell>6 (28.6)</cell></row><row><cell>Highly</cell><cell>23 (62.2)</cell><cell>3 (75.0)</cell><cell>7 (70.0)</cell><cell>13 (56.6)</cell><cell>9 (56.6)</cell><cell>14 (66.7)</cell></row><row><cell cols="2">Did you encounter any problems with the text message system? a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yes</cell><cell>2 (5.3)</cell><cell>0 (0.0)</cell><cell>1 (10.0)</cell><cell>1 (4.2)</cell><cell>1 (6.3)</cell><cell>1 (4.5)</cell></row><row><cell>No</cell><cell>36 (94.7)</cell><cell>4 (100.0)</cell><cell>9 (90)</cell><cell>23 (95.8)</cell><cell>15 (93.7)</cell><cell>21 (95.5)</cell></row><row><cell cols="2">Overall, for you personally, the text messaging was a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Both a burden and helpful</cell><cell>2 (5.4)</cell><cell>1 (25.0)</cell><cell>0 (0.0)</cell><cell>1 (4.3)</cell><cell>0 (0.0)</cell><cell>2 (9.1)</cell></row><row><cell>Mostly a burden and helpful</cell><cell>2 (5.4)</cell><cell>0 (0.0)</cell><cell>0 (0.0)</cell><cell>2 (8.7)</cell><cell>1 (6.7)</cell><cell>1 (4.8)</cell></row><row><cell>Mostly helpful</cell><cell>33 (89.2)</cell><cell>3 (75)</cell><cell>10 (100.0)</cell><cell>20 (87.0)</cell><cell>14 (93.3)</cell><cell>19 (90.5)</cell></row><row><cell cols="2">Did the text messages help you take your oral cancer pills on time? a</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Helped</cell><cell>28 (</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3 .</head><label>3</label><figDesc><div><p xml:id="_3VxWub9"><s xml:id="_nyrBCq3">Summary of Weekly Self-Reported Adherence</s></p></div></figDesc><table><row><cell>WEEK</cell><cell>TM</cell><cell>CONTROL</cell><cell>P</cell></row><row><cell>Week 1</cell><cell></cell><cell></cell><cell>0.53</cell></row><row><cell>Adherent</cell><cell>31 (66.0)</cell><cell>19 (73.1)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>16 (34.0)</cell><cell>7 (26.9)</cell><cell></cell></row><row><cell>Week 2</cell><cell></cell><cell></cell><cell>0.07</cell></row><row><cell>Adherent</cell><cell>26 (55.3)</cell><cell>20 (76.9)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>21 (44.7)</cell><cell>6 (23.1)</cell><cell></cell></row><row><cell>Week 3</cell><cell></cell><cell></cell><cell>0.54</cell></row><row><cell>Adherent</cell><cell>35 (74.5)</cell><cell>21 (80.8)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>12 (25.5)</cell><cell>5 (19.2)</cell><cell></cell></row><row><cell>Week 4</cell><cell></cell><cell></cell><cell>0.01</cell></row><row><cell>Adherent</cell><cell>28 (59.6)</cell><cell>23 (88.5)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>19 (40.4)</cell><cell>3 (11.5)</cell><cell></cell></row><row><cell>Week 5</cell><cell></cell><cell></cell><cell>0.95</cell></row><row><cell>Adherent</cell><cell>34 (72.3)</cell><cell>19 (73.1)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>13 (27.7)</cell><cell>7 (26.9)</cell><cell></cell></row><row><cell>Week 6</cell><cell></cell><cell></cell><cell>0.78</cell></row><row><cell>Adherent</cell><cell>31 (66.0)</cell><cell>18 (69.2)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>16 (34.0)</cell><cell>8 (30.8)</cell><cell></cell></row><row><cell>Week 7</cell><cell></cell><cell></cell><cell>0.45</cell></row><row><cell>Adherent</cell><cell>33 (70.2)</cell><cell>16 (61.5)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>14 (29.8)</cell><cell>10 (38.5)</cell><cell></cell></row><row><cell>Week 8</cell><cell></cell><cell></cell><cell>0.52</cell></row><row><cell>Adherent</cell><cell>29 (61.7)</cell><cell>18 (69.2)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>18 (38.3)</cell><cell>8 (30.8)</cell><cell></cell></row><row><cell>Exit interview</cell><cell></cell><cell></cell><cell>0.42</cell></row><row><cell>Adherent</cell><cell>39 (86.7)</cell><cell>19 (79.2)</cell><cell></cell></row><row><cell>Nonadherent</cell><cell>6 (13.3)</cell><cell>5 (20.8)</cell><cell></cell></row><row><cell>Data are number (%).</cell><cell></cell><cell></cell><cell></cell></row><row><cell>TM, text message.</cell><cell></cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>Table 4 .</head><label>4</label><figDesc><div><p xml:id="_azsnAJG"><s xml:id="_JPN7U4a">Postintervention Least Square Means of Outcomes and Their Standard Errors Adjusted for Baseline Values (Except for Self Efficacy Adherence Medications and Self-Reported Adherence)</s></p></div></figDesc><table><row><cell>Measure</cell><cell>TM</cell><cell>Control</cell><cell>P</cell><cell>ES</cell></row><row><cell>Adherence</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of weeks adherent</cell><cell>6.5 (0.4)</cell><cell>7.2 (0.5)</cell><cell>0.26</cell><cell>0.29</cell></row><row><cell>Symptoms</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Total number</cell><cell>4.9 (0.4)</cell><cell>5.2 (0.6)</cell><cell>0.71</cell><cell>0.09</cell></row><row><cell>Summed severity</cell><cell>23.0 (2.7)</cell><cell>26.5 (3.7)</cell><cell>0.45</cell><cell>0.21</cell></row><row><cell>Summed interference</cell><cell>18.2 (2.7)</cell><cell>21.9 (3.7)</cell><cell>0.41</cell><cell>0.22</cell></row><row><cell>PROMIS</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Depression</cell><cell>44.6 (1.0)</cell><cell>44.2 (1.3)</cell><cell>0.80</cell><cell>0.06</cell></row><row><cell>Physical function</cell><cell>45.7 (0.9)</cell><cell>45.7 (1.3)</cell><cell>0.99</cell><cell>0</cell></row><row><cell>Cognitive function</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Effective action subscale</cell><cell>49.7 (1.5)</cell><cell>53.4 (2.0)</cell><cell>0.15</cell><cell>0.38</cell></row><row><cell>Attentional lapses subscale</cell><cell>23.5 (0.7)</cell><cell>24.1 (0.9)</cell><cell>0.56</cell><cell>0.15</cell></row><row><cell>Interpersonal effectiveness</cell><cell>22.1 (0.7)</cell><cell>23.7 (0.9)</cell><cell>0.18</cell><cell>0.35</cell></row><row><cell>subscale</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Self-efficacy</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>BMQ1</cell><cell>10.4 (0.6)</cell><cell>10.2 (0.8)</cell><cell>0.88</cell><cell>0.04</cell></row><row><cell>BMQ2</cell><cell>16.1 (0.5)</cell><cell>15.9 (0.7)</cell><cell>0.76</cell><cell>0.08</cell></row><row><cell>MASES-R</cell><cell>31.1 (0.3)</cell><cell>31.1 (0.4)</cell><cell>0.83</cell><cell>0.06</cell></row><row><cell>MARS-M</cell><cell>0.3 (0.1)</cell><cell>0.6 (0.2)</cell><cell>0.10</cell><cell>0.44</cell></row><row><cell>Social support</cell><cell>3.7 (0.4)</cell><cell>2.4 (0.5)</cell><cell>0.04</cell><cell>0.54</cell></row><row><cell cols="2">Data are mean (standard error) values.</cell><cell></cell><cell></cell><cell></cell></row><row><cell cols="5">BMQ, Brief Medication Questionnaire; MARS-M, Self Efficacy Adherence</cell></row><row><cell cols="5">Medications; MASES-R, Medication Adherence Self-Efficacy Scale; PROMIS,</cell></row><row><cell cols="3">Patient Reported Outcomes Measurement Information System.</cell><cell></cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>Table 5 .</head><label>5</label><figDesc><div><p xml:id="_9S62Z9r"><s xml:id="_cwYS9fT">Summary of Self-Reported Weekly Symptom Number, Symptom Severity, and Interference with Activities of Daily Living</s></p></div></figDesc><table><row><cell>WEEK, FACTOR EVALUATED</cell><cell>TM LS</cell><cell>CONTROL LS</cell><cell>P</cell></row><row><cell>Week 1</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.6 (0.5)</cell><cell>6.1 (0.7)</cell><cell>0.56</cell></row><row><cell>Symptom severity</cell><cell>23.3 (2.5)</cell><cell>23.3 (3.2)</cell><cell>0.99</cell></row><row><cell>Symptom interference</cell><cell>18.3 (2.6)</cell><cell>21.5 (3.4)</cell><cell>0.46</cell></row><row><cell>Week 2</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.9 (0.5)</cell><cell>5.9 (0.70)</cell><cell>0.99</cell></row><row><cell>Symptom severity</cell><cell>26.5 (2.4)</cell><cell>21.6 (3.2)</cell><cell>0.22</cell></row><row><cell>Symptom interference</cell><cell>21.1 (2.6)</cell><cell>18.8 (3.5)</cell><cell>0.59</cell></row><row><cell>Week 3</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.7 (0.5)</cell><cell>6.1 (0.6)</cell><cell>0.58</cell></row><row><cell>Symptom severity</cell><cell>22.3 (2.4)</cell><cell>22.1 (3.0)</cell><cell>0.96</cell></row><row><cell>Symptom interference</cell><cell>18.2 (2.6)</cell><cell>17.8 (3.2)</cell><cell>0.93</cell></row><row><cell>Week 4</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.4 (0.5)</cell><cell>5.7 (0.6)</cell><cell>0.78</cell></row><row><cell>Symptom severity</cell><cell>22.0 (2.4)</cell><cell>21.9 (2.9)</cell><cell>0.99</cell></row><row><cell>Symptom interference</cell><cell>18 (2.8)</cell><cell>17.3 (3.2)</cell><cell>0.87</cell></row><row><cell>Week 5</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.4 (0.5)</cell><cell>6.0 (0.6)</cell><cell>0.47</cell></row><row><cell>Symptom severity</cell><cell>22.0 (2.4)</cell><cell>24.6 (3.1)</cell><cell>0.50</cell></row><row><cell>Symptom interference</cell><cell>19.6 (2.8)</cell><cell>22.2 (3.4)</cell><cell>0.56</cell></row><row><cell>Week 6</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.8 (0.5)</cell><cell>5.7 (0.6)</cell><cell>0.86</cell></row><row><cell>Symptom severity</cell><cell>23.0 (2.5)</cell><cell>20.8 (2.9)</cell><cell>0.56</cell></row><row><cell>Symptom interference</cell><cell>20.5 (2.9)</cell><cell>17.9 (3.3)</cell><cell>0.56</cell></row><row><cell>Week 7</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>6.1 (0.5)</cell><cell>5.2 (0.7)</cell><cell>0.29</cell></row><row><cell>Symptom severity</cell><cell>23.0 (2.5)</cell><cell>21.5 (3.1)</cell><cell>0.70</cell></row><row><cell>Symptom interference</cell><cell>21.5 (2.7)</cell><cell>20.2 (3.7)</cell><cell>0.77</cell></row><row><cell>Week 8</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.1 (0.5)</cell><cell>5.4 (0.6)</cell><cell>0.70</cell></row><row><cell>Symptom severity</cell><cell>20.5 (2.6)</cell><cell>24.0 (3.1)</cell><cell>0.38</cell></row><row><cell>Symptom interference</cell><cell>17.1 (2.9)</cell><cell>21.9 (3.4)</cell><cell>0.29</cell></row><row><cell>Exit interview</cell><cell></cell><cell></cell><cell></cell></row><row><cell>Number of symptoms</cell><cell>5.0 (0.5)</cell><cell>5.2 (0.6)</cell><cell>0.79</cell></row><row><cell>Symptom severity</cell><cell>22.1 (2.3)</cell><cell>25.1 (3.0)</cell><cell>0.42</cell></row><row><cell>Symptom interference</cell><cell>18.3 (2.4)</cell><cell>21.2 (3.1)</cell><cell>0.45</cell></row><row><cell cols="2">Data are mean (standard error) values.</cell><cell></cell><cell></cell></row></table><note xml:id="_TTQzj2T"><p><s xml:id="_KZJe4U3">LS, least squares.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p xml:id="_jb244Sd"><s xml:id="_zmbXuBa">ª MARY ANN LIE BERT, INC.</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p xml:id="_6e72MBA"><s xml:id="_9PkFBpB">ª M A R Y A N N L I E B E R T , I N C .</s><s xml:id="_46Tqmwb">VOL. 22 NO.</s><s xml:id="_ffdngkh">6 JUNE 2016 TELEMEDICINE and e-HEALTH 499</s></p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p xml:id="_VBRjnkv"><s xml:id="_qvG9BPv">ª M A R Y A N N L I E B E R T , I N C .</s><s xml:id="_UYpgjmS">VOL. 22 NO.</s><s xml:id="_8s2TA22">6 JUNE 2016 TELEMEDICINE and e-HEALTH 505</s></p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head xml:id="_GAvBUdW">Acknowledgments</head><p xml:id="_4ebmJrg"><s xml:id="_6qM9hdA">We thank all of the staff who worked on this project, including <rs type="person">Lauren Calleja</rs>, <rs type="person">Kim Ridenour</rs>, <rs type="person">Sarah Rausch</rs>, and <rs type="person">Michelle Wormser</rs>.</s><s xml:id="_f6KYHaH">We also thank the project facilitators-<rs type="person">John Bachman</rs>, <rs type="person">Elizabeth Bowie</rs>, <rs type="person">Anita Crosena</rs>, <rs type="person">Mary Betsy Johnson</rs>, <rs type="person">Dr. Justin Klamerus</rs>, <rs type="person">Stephen Lott</rs>, <rs type="person">Candise Love</rs>, <rs type="person">Julia Malfield</rs>, <rs type="person">Valentyna Onishchuk</rs>, <rs type="person">Heather Rogers</rs>, <rs type="person">Sandy Sampson</rs>, <rs type="person">Angela Sosin</rs>, <rs type="person">Patricia Thompson</rs>, and <rs type="person">Stephanie Walczak</rs>.</s><s xml:id="_RBK8Qgj">Finally, none of this work would have been possible without the participation of those with cancer.</s><s xml:id="_zA52VUA">Funding for this effort was provided through grant <rs type="grantNumber">1R15CA176595-01</rs> from the <rs type="funder">National Cancer Institute</rs>.</s></p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_pNuyAuu">
					<idno type="grant-number">1R15CA176595-01</idno>
				</org>
			</listOrg>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main" xml:id="_2Sf3ERE">Patient-oncologist cost communication, financial distress, and medication adherence</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Bestvina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Zullig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rushing</surname></persName>
		</author>
		<idno type="DOI">10.1200/jop.2014.001406</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_JkCjWdV">J Oncol Pract</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page" from="162" to="167" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract 2014;10:162-167.</note>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main" xml:id="_kEjHbnp">Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Puts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">A</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tourangeau</surname></persName>
		</author>
		<idno type="DOI">10.1093/annonc/mdt433</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_YVrePTU">Ann Oncol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="564" to="577" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Puts MT, Tu HA, Tourangeau A, et al. Factors influencing adherence to cancer treatment in older adults with cancer: A systematic review. Ann Oncol 2014;25:564-577.</note>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main" xml:id="_V5BGpA3">Adherence to oral antineoplastic agents by cancer patients: Definition and literature review</title>
		<author>
			<persName><forename type="first">F</forename><surname>Bassan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Peter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Houbre</surname></persName>
		</author>
		<idno type="DOI">10.1111/ecc.12124</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_3WgaE7F">Eur J Cancer Care</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="22" to="35" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bassan F, Peter F, Houbre B, et al. Adherence to oral antineoplastic agents by cancer patients: Definition and literature review. Eur J Cancer Care 2014;23:22-35.</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main" xml:id="_8CgcDSW">Treatment with oral anticancer agents: Symptom severity and attribution, and interference with comorbidity management</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Spoelstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sikorskii</surname></persName>
		</author>
		<idno type="DOI">10.1188/15.onf.42-01p</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_WjU66uh">Oncol Nurs Forum</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="80" to="88" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Spoelstra SL, Given CW, Sikorskii A, et al. Treatment with oral anticancer agents: Symptom severity and attribution, and interference with comorbidity management. Oncol Nurs Forum 2014;42:80-88.</note>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main" xml:id="_aMVhAMG">Senior adult oncology, Version 2.2014</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hurria</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wildes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Blair</surname></persName>
		</author>
		<idno type="DOI">10.6004/jnccn.2014.0009</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_GNcSmR5">J Natl Compr Canc Netw</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="82" to="126" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hurria A, Wildes T, Blair SL, et al. Senior adult oncology, Version 2.2014. J Natl Compr Canc Netw 2014;12:82-126.</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main" xml:id="_QagG3ad">mHealth SMS text messaging interventions and to promote medication adherence: An integrative review</title>
		<author>
			<persName><forename type="first">T</forename><surname>Dekoekkoek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Given</surname></persName>
		</author>
		<idno type="DOI">10.1111/jocn.12918</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_8EEe9dR">J Clin Nurs</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2722" to="2735" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">DeKoekkoek T, Given BA, Given CW, et al. mHealth SMS text messaging interventions and to promote medication adherence: An integrative review. J Clin Nurs 2015;24:2722-2735.</note>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main" xml:id="_VYzxDSH">Oral anticancer drugs: How limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients</title>
		<author>
			<persName><forename type="first">V</forename><surname>Prasad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Massey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Fojo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_Z2D9hP7">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1620" to="1629" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Prasad V, Massey P, Fojo T. Oral anticancer drugs: How limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients. J Clin Oncol 2014;32:1620-1629.</note>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main" xml:id="_WzztYRB">Evolutionary dynamics of cancer in response to targeted combination therapy</title>
		<author>
			<persName><forename type="first">I</forename><surname>Bozic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Reiter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Allen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_q6GgczZ">eLife</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="15" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bozic I, Reiter JG, Allen B, et al. Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2013;2:1-15.</note>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main" xml:id="_W7SdtUr">Text messaging as a tool for behavior change in disease prevention and management</title>
		<author>
			<persName><forename type="first">H</forename><surname>Cole-Lewis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kershaw</surname></persName>
		</author>
		<idno type="DOI">10.1093/epirev/mxq004</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_sQ7EMej">Epidemiol Rev</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="56" to="69" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cole-Lewis H, Kershaw T. Text messaging as a tool for behavior change in disease prevention and management. Epidemiol Rev 2010;32:56-69.</note>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main" xml:id="_NtFnUGe">Behavior change interventions delivered by mobile telephone short-message service</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Fjeldsoe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Miller</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.amepre.2008.09.040</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_edRxWQ5">Am J Prev Med</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="165" to="173" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Fjeldsoe BS, Marshall AL, Miller YD. Behavior change interventions delivered by mobile telephone short-message service. Am J Prev Med 2009;36:165-173.</note>
</biblStruct>

<biblStruct xml:id="b10">
	<monogr>
		<idno type="DOI">10.1109/mic.2009.31</idno>
		<ptr target="www.ctia.org/your-wireless-life/how-wireless-works/wireless-quick-facts" />
		<title level="m" xml:id="_pm5Stmj">CTIA-The Wireless Association. Wireless quick facts</title>
		<imprint>
			<date type="published" when="2015-08-14">August 14, 2015</date>
		</imprint>
	</monogr>
	<note>6/14 update. Available at</note>
	<note type="raw_reference">CTIA-The Wireless Association. Wireless quick facts, 6/14 update. Available at www.ctia.org/your-wireless-life/how-wireless-works/wireless-quick-facts (last accessed August 14, 2015).</note>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<idno type="DOI">10.1037/e358912004-006</idno>
		<title level="m" xml:id="_C7H2WyF">Using health text messages to improve consumer health knowledge, behaviors, and outcomes: An environmental scan</title>
		<meeting><address><addrLine>Rockville, MD</addrLine></address></meeting>
		<imprint>
			<publisher>U.S. Department of Health and Human Services</publisher>
			<date type="published" when="2014">2014</date>
		</imprint>
		<respStmt>
			<orgName>Health Resources and Services Administration, U.S. Department of Health and Human Services</orgName>
		</respStmt>
	</monogr>
	<note type="raw_reference">Health Resources and Services Administration, U.S. Department of Health and Human Services. Using health text messages to improve consumer health knowledge, behaviors, and outcomes: An environmental scan. Rockville, MD: U.S. Department of Health and Human Services, 2014.</note>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main" xml:id="_q8gNEjH">Self-efficacy: Toward a unifying theory of behavioral change</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bandura</surname></persName>
		</author>
		<idno type="DOI">10.1037//0033-295x.84.2.191</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kWJ4dGb">Psychol Rev</title>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="page" from="191" to="215" />
			<date type="published" when="1977">1977</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Bandura A. Self-efficacy: Toward a unifying theory of behavioral change. Psychol Rev 1977;84:191-215.</note>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main" xml:id="_s9JqbRW">Developing a theory driven text messaging intervention for addiction care with user driven content</title>
		<author>
			<persName><forename type="first">F</forename><surname>Muench</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Weiss</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kuerbis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_UUQFJFs">Psychol Addict Behav</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="315" to="321" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Muench F, Weiss RA, Kuerbis A, et al. Developing a theory driven text messaging intervention for addiction care with user driven content. Psychol Addict Behav 2013;27:315-321.</note>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main" xml:id="_Huv2R3U">Psychosocial factors and medication adherence among patients with coronary heart disease: A text messaging intervention</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Howie-Esquivel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Whooley</surname></persName>
		</author>
		<idno type="DOI">10.1177/1474515114537024</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_EfXGWqZ">Eur J Cardiovasc Nurs</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="264" to="273" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Park LG, Howie-Esquivel J, Whooley MA, et al. Psychosocial factors and medication adherence among patients with coronary heart disease: A text messaging intervention. Eur J Cardiovasc Nurs 2015;14:264-273.</note>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main" xml:id="_RtuQUzy">A randomized controlled trial of the feasibility and preliminary efficacy of text messages on medication adherence in adults prescribed oral anti-cancer agents: Study protocol</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Spoelstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sikorskii</surname></persName>
		</author>
		<idno type="DOI">10.1111/jan.12714</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4XkSkF2">J Adv Nurs</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="2965" to="2976" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Spoelstra SL, Given CW, Sikorskii A, et al. A randomized controlled trial of the feasibility and preliminary efficacy of text messages on medication adherence in adults prescribed oral anti-cancer agents: Study protocol. J Adv Nurs 2015;71:2965-2976.</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main" xml:id="_XVDdF6q">An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: An exploratory study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Spoelstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Given</surname></persName>
		</author>
		<idno type="DOI">10.1097/ncc.0b013e3182551587</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_kFtad8E">Cancer Nurs</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="18" to="28" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Spoelstra SL, Given BA, Given CW, et al. An intervention to improve adherence and management of symptoms for patients prescribed oral chemotherapy agents: An exploratory study. Cancer Nurs 2013;36:18-28.</note>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main" xml:id="_jCUhAtW">A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents</title>
		<author>
			<persName><forename type="first">V</forename><surname>Decker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Spoelstra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Miezo</surname></persName>
		</author>
		<idno type="DOI">10.1097/ncc.0b013e3181b31114</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_AbD27QS">Cancer Nurs</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="20" to="E29" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Decker V, Spoelstra S, Miezo E, et al. A pilot study of an automated voice response system and nursing intervention to monitor adherence to oral chemotherapy agents. Cancer Nurs 2009;32:E20-E29.</note>
</biblStruct>

<biblStruct xml:id="b18">
	<monogr>
		<title level="m" type="main" xml:id="_GCgbHYw">Increasing awareness of relative dose intensity in an evidence-based practice</title>
		<author>
			<persName><surname>Amgen</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2008">2008</date>
			<publisher>AMGEN</publisher>
			<pubPlace>Thousand Oaks, CA</pubPlace>
		</imprint>
	</monogr>
	<note type="raw_reference">AMGEN. Increasing awareness of relative dose intensity in an evidence-based practice. Thousand Oaks, CA: AMGEN, 2008.</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main" xml:id="_qbRT7gS">Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients&apos; short and long-term outcome in taxane-and anthracycline-based chemotherapy of metastatic breast cancer-A pooled analysis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Loibl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Skacel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Nekljudova</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2407-11-131</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6CCvrxe">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">131</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Loibl S, Skacel T, Nekljudova V, et al. Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients&apos; short and long-term outcome in taxane-and anthracycline-based chemotherapy of metastatic breast cancer-A pooled analysis. BMC Cancer 2011;11:131.</note>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main" xml:id="_bvK79yc">Relative dose intensity delivered to patients with early breast cancer: Canadian experience</title>
		<author>
			<persName><forename type="first">S</forename><surname>Raza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Younus</surname></persName>
		</author>
		<idno type="DOI">10.3747/co.v16i6.311</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_fbBbr75">Curr Oncol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="8" to="12" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Raza S, Welch S, Younus J. Relative dose intensity delivered to patients with early breast cancer: Canadian experience. Curr Oncol 2009;16:8-12.</note>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main" xml:id="_HrScPw4">Establishing mild, moderate, and severe scores for cancer related symptoms: How consistent and clinically meaningful are interference based severity cut points?</title>
		<author>
			<persName><forename type="first">B</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sikorskii</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jpainsymman.2007.03.012</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_VyxdpSz">J Pain Symptom Manag</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="126" to="135" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Given B, Given C, Sikorskii A, et al. Establishing mild, moderate, and severe scores for cancer related symptoms: How consistent and clinically meaningful are interference based severity cut points? J Pain Symptom Manag 2008;35:126-135.</note>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main" xml:id="_Wax8mmg">Deconstruction of nurse-delivered patient self-management interventions for symptom management: Factors related to delivery enactment and response</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Given</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sikorskii</surname></persName>
		</author>
		<idno type="DOI">10.1007/s12160-010-9191-7</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_vVRmaPZ">Ann Behav Med</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="99" to="113" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Given CW, Given BA, Sikorskii A, et al. Deconstruction of nurse-delivered patient self-management interventions for symptom management: Factors related to delivery enactment and response. Ann Behav Med 2010;40:99-113.</note>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main" xml:id="_GcnsbCA">The Attentional Function Index-A self-report cognitive measure</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cimprich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Visovatti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Ronis</surname></persName>
		</author>
		<idno type="DOI">10.1002/pon.1729</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ACFUBDp">Psychooncology</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="194" to="202" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cimprich B, Visovatti M, Ronis DL. The Attentional Function Index-A self-report cognitive measure. Psychooncology 2011;20:194-202.</note>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main" xml:id="_RDuQt4S">Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS Ò ): Depression, anxiety, and anger</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Pilkonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Reise</surname></persName>
		</author>
		<idno type="DOI">10.1177/1073191111411667</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_M2B72Wy">Assessment</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="263" to="283" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Pilkonis PA, Choi SW, Reise SP, et al. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS Ò ): Depression, anxiety, and anger. Assessment 2011;18:263-283.</note>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main" xml:id="_4YRr2Q2">Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients</title>
		<author>
			<persName><forename type="first">G</forename><surname>Ogedegbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Mancuso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Allegrante</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0895-4356(03)00053-2</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_z3TE3Hq">J Clin Epidemiol</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="520" to="529" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Ogedegbe G, Mancuso CA, Allegrante JP, et al. Development and evaluation of a medication adherence self-efficacy scale in hypertensive African-American patients. J Clin Epidemiol 2003;56:520-529.</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main" xml:id="_4EVd3JJ">Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses</title>
		<author>
			<persName><forename type="first">K</forename><surname>Thompson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kulkarni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sergejew</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0920-9964(99)00130-9</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_ErCwCeV">Schizophr Res</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="241" to="247" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Thompson K, Kulkarni J, Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. Schizophr Res 2000;42:241-247.</note>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main" xml:id="_nBTwnhH">The Beliefs about Medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication</title>
		<author>
			<persName><forename type="first">R</forename><surname>Horne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Weinman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hankins</surname></persName>
		</author>
		<idno type="DOI">10.1080/08870449908407311</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6t3vk9N">Psychol Health</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1" to="24" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Horne R, Weinman J, Hankins M. The Beliefs about Medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1-24.</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main" xml:id="_qtSTcbY">Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lehavot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Huh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Walters</surname></persName>
		</author>
		<idno type="DOI">10.1089/apc.2010.0314</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_txznPxB">AIDS Patient Care STDS</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="181" to="189" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Lehavot K, Huh D, Walters KL, et al. Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence. AIDS Patient Care STDS 2011;25:181-189.</note>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main" xml:id="_C3k5D8b">A power primer</title>
		<author>
			<persName><forename type="first">J</forename><surname>Cohen</surname></persName>
		</author>
		<idno type="DOI">10.1037//0033-2909.112.1.155</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_t3msaHF">Psychol Bull</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="155" to="159" />
			<date type="published" when="1992">1992</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Cohen J. A power primer. Psychol Bull 1992;112:155-159.</note>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main" xml:id="_N9AB6hu">On effect size</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kelley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">J</forename><surname>Preacher</surname></persName>
		</author>
		<idno type="DOI">10.1037/a0028086</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_jKbP2q7">Psychol Methods</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="137" to="152" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Kelley K, Preacher KJ. On effect size. Psychol Methods 2012;17:137-152.</note>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main" xml:id="_BjMXtpE">Adherence to disease management programs in patients with COPD</title>
		<author>
			<persName><forename type="first">J</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Stewart</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j" xml:id="_6v8cJ4b">Int J Chron Obstruct Pulmon Dis</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="253" to="262" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">George J, Kong DC, Stewart K. Adherence to disease management programs in patients with COPD. Int J Chron Obstruct Pulmon Dis 2007;2:253-262.</note>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main" xml:id="_hN9f75p">Techniques for measuring medication adherence in hypertensive patients in outpatient settings: Advantages and limitations</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Hawkshead</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Krousel-Wood</surname></persName>
		</author>
		<idno type="DOI">10.2165/00115677-200715020-00006</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_y7Jgu4G">Dis Manag Health Out</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="109" to="118" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Hawkshead JJ, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: Advantages and limitations. Dis Manag Health Out 2007;15:109-118.</note>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main" xml:id="_NQzxvw9">Measurement of adherence to antiretroviral medications</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Potoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Capitano</surname></persName>
		</author>
		<idno type="DOI">10.1097/00126334-200212153-00003</idno>
	</analytic>
	<monogr>
		<title level="j" xml:id="_4E9gqWC">J Acquir Immune Defic Syndr</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">Suppl 3</biblScope>
			<biblScope unit="page" from="103" to="S106" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
	<note type="raw_reference">Paterson DL, Potoski B, Capitano B. Measurement of adherence to antiretroviral medications. J Acquir Immune Defic Syndr 2002;31(Suppl 3):S103-S106.</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
